MetaCap

Boundless Bio (BOLD) vs XBiotech (XBIT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Boundless Bio (BOLD) has outperformed XBiotech (XBIT) over the past year, gaining 105.3% versus a loss of 24.1%. Boundless Bio is the larger company by market cap ($54.8 million vs $52.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BOLD+105.31%XBIT-24.12%
+175%+70%-36%
Nov 21, 20251 yearNov 20, 2026
BOLD-83.72%XBIT-78.72%
+19%-40%-98%
Mar 25, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BOLD versus XBIT key metrics
MetricBOLDXBIT
Share price$2.32$1.73
Market cap$54.78M$52.74M
1-day change-2.52%+2.98%
YTD return+93.33%-27.62%
1-year return+105.31%-24.12%
5-year return—-86.48%
Forward P/E—13.31
EPS (TTM)$-2.46$-1.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-58.20M$-45.54M
52-week high$3.16$2.73
52-week low$0.961$1.61
Distance from 52-week high-26.68%-36.63%
Analyst consensusnone—
Avg. price target upside+72.41%—
Average volume131.34K64.77K
Shares outstanding23.61M30.49M
Employees2887
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BOLD has outperformed XBIT by 129.4 percentage points over the past year.

About Boundless Bio

BOLD stock →

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

About XBiotech

XBIT stock →

XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

BOLD vs XBIT FAQ

Which is bigger, Boundless Bio or XBiotech?

Boundless Bio (BOLD) is larger, with a market capitalization of $54.78M compared with $52.74M for XBiotech (XBIT).

Which stock has performed better over the past year, BOLD or XBIT?

BOLD returned +105.31% over the past 12 months, compared with -24.12% for XBIT (price return, excluding dividends). Past performance does not predict future results.

Are Boundless Bio and XBiotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons